Metabolism, Excretion, and Pharmacokinetics of [ 14 C]‐Cefiderocol (S‐649266), a Siderophore Cephalosporin, in Healthy Subjects Following Intravenous Administration-Reference-Cited by-同舟云学术

Metabolism, Excretion, and Pharmacokinetics of [ 14 C]‐Cefiderocol (S‐649266), a Siderophore Cephalosporin, in Healthy Subjects Following Intravenous Administration

Published:2019-02-07 Issue:7 Volume:59 Page:958-967
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:The Journal of Clinical Pharmacology

Author:

Miyazaki Shiro¹,Katsube Takayuki¹,Shen Helen²,Tomek Charles³,Narukawa Yukitoshi¹

Affiliation:

1. Shionogi & Co., Ltd. Osaka Japan

2. QPS LLC Newark DE USA

3. Celerion Lincoln NE USA

Funder

Shionogi Inc

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jcph.1386

Reference22 articles.

1. In vitroantimicrobial activity of S-649266, a catechol-substituted siderophore cephalosporin, when tested against non-fermenting Gram-negative bacteria

2. In Vitro Antimicrobial Activity of a Siderophore Cephalosporin, S-649266, against Enterobacteriaceae Clinical Isolates, Including Carbapenem-Resistant Strains

3. NakamuraR TobaS TsujiM et al.S‐649266 novel siderophore cephalosporin: IV.In vivoefficacy in various murine infection models. Presented at the 54thIntersci Conf Antimicrob Agents Chemother(ICAAC 2014); September 5‐9 2014; Washington DC. Poster F‐1558.

4. Efficacy of Cefiderocol against Carbapenem-Resistant Gram-Negative Bacilli in Immunocompetent-Rat Respiratory Tract Infection Models Recreating Human Plasma Pharmacokinetics

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacokinetics, Safety and Tolerability of Single-dose or Multiple-dose Cefiderocol in Hospitalized Pediatric Patients Three Months to Less Than Eighteen Years Old With Infections Treated With Standard-of-care Antibiotics in the PEDI-CEFI Phase 2 Study;Pediatric Infectious Disease Journal;2024-09-04

2. In vitro resistance development gives insights into molecular resistance mechanisms against cefiderocol;The Journal of Antibiotics;2024-07-30

3. Continuous infusion of cefiderocol in a critically ill patient with continuous venovenous haemofiltration;British Journal of Clinical Pharmacology;2023-09-20

4. Prospective role of cefiderocol in the management of carbapenem-resistant Acinetobacter baumannii infections: Review of the evidence;International Journal of Antimicrobial Agents;2023-08

5. Treatment of critically ill patients with cefiderocol for infections caused by multidrug-resistant pathogens: review of the evidence;Annals of Intensive Care;2023-06-15